Published in J Clin Oncol on October 11, 2011
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol (2015) 1.67
Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer (2013) 1.26
Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res (2013) 1.26
Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther (2010) 1.07
Tumor stroma as targets for cancer therapy. Pharmacol Ther (2012) 1.06
Automated extraction of reported statistical analyses: towards a logical representation of clinical trial literature. AMIA Annu Symp Proc (2012) 0.95
The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy. PLoS One (2013) 0.85
Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment. Cancer J (2013) 0.81
Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials. PLoS One (2016) 0.80
Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review. Mol Clin Oncol (2014) 0.80
Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy. World J Surg Oncol (2015) 0.79
COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128. Int J Gynecol Cancer (2013) 0.79
Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma. World J Surg Oncol (2014) 0.78
Expression of STAT5, COX-2 and PIAS3 in correlation with NSCLC histhopathological features. PLoS One (2014) 0.78
Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again. Oncologist (2015) 0.78
Revisiting the role of COX-2 inhibitor for non-small cell lung cancer. Transl Lung Cancer Res (2015) 0.77
Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer. J Clin Oncol (2012) 0.77
Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer? Br J Clin Pharmacol (2015) 0.75
Correlation between serum IL-1β and miR-144-3p as well as their prognostic values in LUAD and LUSC patients. Oncotarget (2016) 0.75
Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review. BMC Cancer (2016) 0.75
Potency of non-steroidal anti-inflammatory drugs in chemotherapy. Mol Clin Oncol (2014) 0.75
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol (2005) 6.57
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst (2007) 4.40
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet (2007) 3.85
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature (2011) 3.22
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer (2006) 2.33
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.22
Exercise capacity before and after an 8-week multidisciplinary inpatient rehabilitation program in lung cancer patients: a pilot study. Lung Cancer (2006) 2.07
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol (2009) 2.06
Cigarette smoke-induced emphysema: A role for the B cell? Am J Respir Crit Care Med (2006) 2.05
Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst (2012) 1.99
Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med (2012) 1.78
Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? Hum Pathol (2006) 1.70
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol (2013) 1.59
Risk factors for osteoporosis in Caucasian patients with moderate chronic obstructive pulmonary disease: a case control study. Bone (2012) 1.56
MicroRNAs, macrocontrol: regulation of miRNA processing. RNA (2010) 1.56
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol (2012) 1.52
Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma. Haematologica (2011) 1.46
Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia (2009) 1.44
Four-dimensional computed tomographic analysis of esophageal mobility during normal respiration. Int J Radiat Oncol Biol Phys (2007) 1.43
Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest (2010) 1.43
Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases. J Thorac Oncol (2014) 1.42
BcR-induced apoptosis involves differential regulation of C16 and C24-ceramide formation and sphingolipid-dependent activation of the proteasome. J Biol Chem (2003) 1.39
HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol (2007) 1.39
Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol (2009) 1.34
HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood (2007) 1.30
Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol (2005) 1.29
Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. J Clin Oncol (2006) 1.24
A high throughput experimental approach to identify miRNA targets in human cells. Nucleic Acids Res (2009) 1.24
Selective targeting of homologous DNA recombination repair by gemcitabine. Int J Radiat Oncol Biol Phys (2003) 1.23
Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol (2008) 1.22
Rapid generation of microRNA sponges for microRNA inhibition. PLoS One (2012) 1.17
miRNA profiling of B-cell subsets: specific miRNA profile for germinal center B cells with variation between centroblasts and centrocytes. Lab Invest (2009) 1.16
Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod Pathol (2009) 1.15
Proteomics analysis of Hodgkin lymphoma: identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes. Blood (2007) 1.12
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer (2005) 1.12
A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer (2009) 1.11
Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood (2012) 1.11
Immuno-miRs: critical regulators of T-cell development, function and ageing. Immunology (2015) 1.11
Treatment of haemothorax. Respir Med (2010) 1.10
Novel insights into pathological changes in muscular arteries of radiotherapy patients. Radiother Oncol (2009) 1.08
Genomic aberrations in squamous cell lung carcinoma related to lymph node or distant metastasis. Lung Cancer (2009) 1.07
Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. J Clin Oncol (2009) 1.07
The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. Cancer Epidemiol Biomarkers Prev (2006) 1.07
Strongly enhanced IL-10 production using stable galectin-1 homodimers. Mol Immunol (2006) 1.06
MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma. Br J Haematol (2010) 1.05
Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients. Int J Radiat Oncol Biol Phys (2010) 1.04
Generation of miRNA sponge constructs. Methods (2012) 1.04
Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques. Int J Radiat Oncol Biol Phys (2010) 1.04
Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol (2010) 1.03
Motion analysis of 100 mediastinal lymph nodes: potential pitfalls in treatment planning and adaptive strategies. Int J Radiat Oncol Biol Phys (2008) 1.02
Correlates of osteoporosis in chronic obstructive pulmonary disease: An underestimated systemic component. Respir Med (2009) 1.02
Unstable proximal extraarticular tibia fractures: a biomechanical evaluation of four methods of fixation. J Orthop Trauma (2004) 1.01
BCL6 alternative breakpoint region break and homozygous deletion of 17q24 in the nodular lymphocyte predominance type of Hodgkin's lymphoma-derived cell line DEV. Hum Pathol (2006) 0.99
Targeting apoptosis pathways in lung cancer. Cancer Lett (2010) 0.98
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study. Cancer (2011) 0.98
Dual role of miR-21 in CD4+ T-cells: activation-induced miR-21 supports survival of memory T-cells and regulates CCR7 expression in naive T-cells. PLoS One (2013) 0.97
Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer (2011) 0.96
Current smoking-specific gene expression signature in normal bronchial epithelium is enhanced in squamous cell lung cancer. J Pathol (2009) 0.96
Dimeric galectin-1 induces IL-10 production in T-lymphocytes: an important tool in the regulation of the immune response. J Pathol (2004) 0.95
Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas. Am J Pathol (2005) 0.94
Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer (2004) 0.94
Can an online clinical data management service help in improving data collection and data quality in a developing country setting? Trials (2011) 0.94
Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures. J Bone Miner Res (2011) 0.94
Microarray amplification bias: loss of 30% differentially expressed genes due to long probe - poly(A)-tail distances. BMC Genomics (2007) 0.94
P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression. Clin Cancer Res (2005) 0.93
Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features. Blood (2003) 0.93
Iris metastasis in small-cell lung carcinoma. J Thorac Oncol (2007) 0.92
Cytokine gene expression profile distinguishes CD4+/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma from their tonsillar counterparts. J Pathol (2006) 0.92
Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands. Health Qual Life Outcomes (2012) 0.92
Protease activity of plasma hemopexin. Kidney Int (2005) 0.92
The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile. Lab Invest (2008) 0.92
Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer (2007) 0.92
Optimization of intradermal vaccination by DNA tattooing in human skin. Hum Gene Ther (2009) 0.91
Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J (2002) 0.91
Bowel exposure in rectal cancer IMRT using prone, supine, or a belly board. Radiother Oncol (2011) 0.91
HLA associations in classical Hodgkin lymphoma: EBV status matters. PLoS One (2012) 0.90
Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin. Lung Cancer (2012) 0.89
Prognostic parameters for acute esophagus toxicity in intensity modulated radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer. Radiother Oncol (2013) 0.89
Assessment of tracheal temperature and humidity in laryngectomized individuals and the influence of a heat and moisture exchanger on tracheal climate. Head Neck (2008) 0.89
MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. Int J Cancer (2004) 0.88
A new heat and moisture exchanger for laryngectomized patients: endotracheal temperature and humidity. Respir Care (2011) 0.88
Production of hemopexin by TNF-alpha stimulated human mesangial cells. Kidney Int (2003) 0.88